Overview

A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)

Status:
Recruiting

Trial end date:
2022-07-31

Target enrollment:

Participant gender:

Summary

The primary objective of this study is to demonstrate the efficacy of inhaled treprostinil compared to placebo in improving exercise ability as measured by change from baseline in 6-Minute Walk Distance (6MWD) following 12 weeks of active treatment in participants with PH-COPD.

Phase:

Phase 3

Details

Lead Sponsor:

United Therapeutics

Treatments:

Pharmaceutical Solutions
Treprostinil